SCH 532706

Drug Profile

SCH 532706

Latest Information Update: 20 Jun 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Class Antivirals; Small molecules
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 08 Aug 2011 No development reported - Phase-I for HIV-1 infections (Combination therapy) in Australia (PO)
  • 06 Mar 2007 Phase-I clinical trials in HIV-1 infections (Combination therapy) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top